SecBot SecBot
PRESS-RELEASE ·Filed May 5, 2026

RYTM

Rhythm Pharmaceuticals, Inc.
BULLISH
Impact 7/10
Horizonweeks Processed6mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▲ Bullish

The strong Q1 beat and rapid early adoption of IMCIVREE in acquired HO (150+ patient start forms in 6 weeks) signal accelerating commercial traction. Watch for upcoming catalysts: Phase 2 PWS data (Q2 2026), RM-718 data (mid-2026), and Japan PMDA decision (H2 2026).

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$92.31
T+0 close · May 5, 2026 · via day close
Latest settled
+14.55%
T+60 · $105.74
Vs SPY
+11.81%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 5 $92.31entry
  2. T+1 · 7mo ago +4.66%α +3.27% · $96.61
  3. T+5 · 6mo ago −1.08%α −3.07% · $91.31
  4. T+20 · 6mo ago −8.62%α −13.58% · $84.35
  5. T+60 · 4mo ago +14.55%α +11.81% · $105.74

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Rhythm Pharmaceuticals reported Q1 2026 revenue of $60.1M, beating the $56.1M consensus, and an EPS loss of -$0.73, beating the -$0.86 estimate by 15.2%. The beat was driven by strong IMCIVREE sales, including the newly approved acquired hypothalamic obesity indication, but the company's net loss widened to -$56.7M from -$50.8M a year ago, and operating expenses surged 41% YoY.

Key Financial Metrics

EPS
−$0.73
est −$0.86 · +15.1%
Revenue
$60.1M
est $56.1M · +7.2% · +59.4% YoY
Rating
beat

Key Facts

  • Q1 2026 revenue $60.1M vs consensus $56.1M (beat)
  • Q1 2026 EPS -$0.73 vs consensus -$0.86 (15.2% beat)
  • IMCIVREE approved by FDA for acquired hypothalamic obesity on March 19, 2026; >150 patient start forms received in first 6 weeks
  • European Commission granted Marketing Authorization for IMCIVREE in acquired HO on May 1, 2026
  • Net loss widened to -$56.7M from -$50.8M YoY; operating expenses rose to $112.5M from $79.7M
  • Cash position $340.6M as of March 31, 2026; company expects sufficient runway for at least 24 months
  • Non-GAAP operating expense guidance for FY2026: $385M-$415M

Financial Impact

Revenue beat of $4.0M (7.1%) vs consensus; EPS beat of $0.13 (15.2%) vs consensus; net loss widened by $5.9M YoY

revenueepsnet lossoperating expenses

Risk Factors

  • Operating expenses growing faster than revenue (41% YoY vs 59% revenue growth)
  • EMANATE Phase 3 trial missed primary endpoint in March 2026, creating pipeline uncertainty
  • Sequential U.S. revenue declined 5% QoQ due to inventory and insurance transitions
  • High cash burn rate ($48.3M in Q1 2026) despite $340.6M cash position

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
91% bullish (22 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3287506

Track record

26 reports on RYTM

Performance horizon

9 of 13 bullish or bearish reports moved the stock their way by T+5. Best: +32.06% at T+60 after the May 1, 2026 report. 10 of 13 went positive at some point.

Filters
  1. Nov 16, 2026today Press Release Bullish 5/10 Entry $107.48 Now $107.48 +0.00% settles Nov 24
  2. Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $110.68 to $112.16 Now $107.48 −2.89% ▲ +1.34% +2.25% vs SPY
  3. Nov 4, 202612d ago Press Release Bullish 5/10 Entry $110.68 to $112.16 Now $107.48 −2.89% ▲ +1.34% +2.25% vs SPY
  4. Nov 3, 202613d ago 8-K Bullish 6/10 No price data
  5. Nov 3, 202613d ago Press Release Bullish 6/10 Entry $86.44 to $113.95 Now $107.48 +24.34% ▲ +31.83% +32.41% vs SPY
  6. Nov 2, 202613d ago Press Release Neutral 5/10 Entry $86.44 to $113.95 Now $107.48 +24.34% ▲ +31.83% +32.41% vs SPY
  7. Oct 13, 20264w ago Press Release Bullish 6/10 Entry $86.71 to $88.62 Now $107.48 +23.95% ▲ +2.20% +1.75% vs SPY
  8. Oct 13, 20264w ago SC 13G Neutral 3/10 Entry $86.61 to $90.20 Now $107.48 +24.10% ▲ +4.14% +5.30% vs SPY
  9. Sep 14, 20269w ago 144 Bearish 5/10 Entry $96.77 to $99.27 Now $107.48 −11.07% ▼ −2.58% −0.47% vs SPY
  10. Aug 17, 202613w ago Insider Cluster Bearish 6/10 Entry $115.25 to $113.35 Now $107.48 +6.74% ▲ +1.65% +1.45% vs SPY
Showing 10 of 26

US Market Status

Market Closed · Opens Wed (11h 38m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 5, 2026